Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00905450 · ClinicalTrials.gov registry record · Phase 2
Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 415
- Enrollment target
NCT00905450: Completed Phase 2 study, sponsored by Bausch & Lomb Incorporated.
NCT00905450 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 415 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (212% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00905450, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 415 participants
- Enrollment target
Study Summary
This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.
Primary Outcome
Anterior chamber (AC) cells will be assessed using a 0 to 4 grading scale by an ophthalmologist using slip lamp biomicroscopy. A slit lamp examination of the lids, conjunctiva, limbus, cornea, anterior chamber, vitreous, and lens was performed without pupil dilation. Accumulation of white blood cells in aqueous was assessed. Pigment cells and red blood cells are to be ignored. The grades were defined as: 0 = No cells seen; 1 = 1 - 5 cells; 2 = 6 - 15 cells; 3 = 16 - 30 cells; 4 = \>30 cells. Com
Interventions
- DRUG BOL-303242-X
- DRUG Vehicle for BOL-303242-X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
What the finished NCT00905450 record still lists
NCT00905450 is an interventional study that assigns participants to a tested intervention. The registered 415 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (212% higher).
The record links to 0 conditions, and to 2 interventions - of which BOL-303242-X is the first listed.
NCT00905450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00905450 about?
NCT00905450 is a clinical study titled "Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery". This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.
What is the current status of trial NCT00905450?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 415 participants. The study started on 2009-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00905450?
The interventions under investigation include: BOL-303242-X (DRUG), Vehicle for BOL-303242-X (DRUG).
Who is sponsoring clinical trial NCT00905450?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00905450's enrollment target sits among peer trials
415 93rd of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05142605 · 415 participants · NA
Evaluation of Grief Therapy Approaches for Bereaved Parents
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia